Mat Zuki Bin Mat Jaeb Malaysia

Biography . Dato' Dr Mat Zuki Bin Mat Jaeb is a Senior Consultant Respiratory Physician at Hospital Raja Perempuan Zainab II (HRPZ II), Kota Bharu, Kelantan, and currently serves as the National Head of Respiratory Medicine Services for the Ministry of Health Malaysia. Born in Pasir Mas, Kelantan, he graduated with an MBBS from the University of Malaya and later obtained a Master’s in Internal Medicine from Universiti Sains Malaysia. He completed fellowship training in Respiratory Medicine in 2008 at the Institute of Respiratory Medicine, Kuala Lumpur, followed by advanced training in Interventional Pulmonology in Marseille, France. Dato’ Dr. Mat Zuki has held numerous leadership roles at national and institutional levels, including Chairman of the National Respiratory Drug Committee, Chairman of the Technical Working Group for the National Lung Health Initiatives, Chairman for the Technical Working Group for the Lung Cancer National Strategic Plan (NSP), and Chairman of the Medical and Dental Advisory Board at HRPZ II. His clinical and research interests include chronic obstructive pulmonary disease (COPD), severe asthma, tuberculosis—particularly drug-resistant TB—and interstitial lung diseases. He has served as a principal investigator in multiple international clinical trials and actively contributes to national clinical practice guidelines and respiratory training programmes. An accomplished speaker and educator, he regularly presents at regional and international respiratory conferences and serves as an examiner and trainer for respiratory subspecialty programmes in Malaysia. His research publications focus on tuberculosis, COPD, and respiratory health outcomes in Malaysia, reflecting his commitment to advancing lung health policy, research, and clinical care. Executive Biography Dato’ Dr. Mat Zuki Mat Jaeb is a distinguished Senior Consultant Respiratory Physician at Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, and currently serves as the National Head of Respiratory Medicine Subspecialty for the Ministry of Health Malaysia. With over two decades of clinical, academic, and leadership experience, he is widely recognised as one of Malaysia’s leading experts in respiratory medicine and lung health policy. He obtained his medical degree from the University of Malaya and later completed a Master’s in Internal Medicine at Universiti Sains Malaysia. He subsequently undertook specialist fellowship training in Respiratory Medicine at the Institute of Respiratory Medicine, Ministry of Health Malaysia, followed by advanced subspecialty training in Interventional Pulmonology in Marseille, France. His international experience has strengthened his expertise in advanced respiratory procedures and complex lung diseases. At the national level, Dato’ Dr. Mat Zuki plays a pivotal role in shaping respiratory healthcare delivery, workforce development, and clinical governance in Malaysia. He is a member of the GOLD COPD Assembly and has chaired and contributed to numerous national committees covering respiratory drug policy, respiratory disease guidelines, national tuberculosis control programmes, subspecialty training, and clinical mortality reviews. His leadership extends to strategic initiatives aimed at strengthening lung health services, improving access to advanced therapies, and enhancing patient outcomes across the country, particularly through the National Lung Health Initiatives 2025–2030. His clinical and research interests include chronic obstructive pulmonary disease, severe asthma, interstitial lung diseases, bronchiectasis, and drug-resistant tuberculosis. He has served as a principal investigator and national lead in multiple international clinical trials and has contributed extensively to Malaysian clinical practice guidelines and consensus statements. An active academic and sought-after speaker, he regularly delivers keynote lectures at national respiratory conferences and mentors the next generation of respiratory specialists. Dato’ Dr. Mat Zuki remains deeply committed to advancing respiratory medicine through evidence-based policy, multidisciplinary collaboration, and innovation in clinical care. His work continues to influence national lung health strategies and strengthen Malaysia’s position in regional respiratory leadership.
Job Title
Respiratory Consultant
Faculty / Department / Division
Respiratory Unit
Institution / Organisation
Hospital Raja Perempuan Zainab II

20 November 2026, Friday

Time Session
09:30
11:00
Bazli Bahar Chairperson Malaysia
  • Diego Silva Speaker Australia
  • Zamzurina Abu Bakar Speaker Malaysia
    Malaysia’s transition from toxic, 20-month injectable regimens to 6-month all-oral BPaLM therapy has revolutionized drug-resistant tuberculosis management, cutting treatment duration by 70%, reducing drug costs by 80%, and shortening median culture conversion to just 32 days while averting irreversible ototoxicity. Coupled with nationwide decentralized molecular testing and genomic resistance surveillance, this operational framework delivers a proven, patient-centred model for reimagining drug-resistant respiratory care across the Asia-Pacific.
  • Mat Zuki Bin Mat Jaeb Speaker Malaysia
    From Control to Elimination: Evaluating Malaysia’s Tuberculosis Journey and Future Priorities Dato’ Dr Mat Zuki Mat Jaeb Abstract Tuberculosis (TB) remains a significant public health challenge in Malaysia despite sustained national control efforts and improvements in treatment outcomes. In 2025, Malaysia reported 26,672 TB cases, corresponding to a notification rate of 77.9 per 100,000 population, while 2,392 deaths highlighted persistent challenges in reducing TB mortality. These findings underscore the need to accelerate progress towards the World Health Organization’s End TB targets. This lecture evaluates Malaysia’s TB epidemiological trends, achievements, persistent gaps, and strategic priorities for transitioning from disease control towards elimination. Key challenges include delayed diagnosis, ongoing community transmission, undetected TB infection, inadequate preventive treatment coverage, comorbidities, population mobility, and disparities in healthcare access. Although treatment success remains encouraging, conventional approaches focusing predominantly on diagnosing and treating active disease are insufficient to interrupt transmission and achieve elimination targets. Malaysia’s National Strategic Plan to End TB 2021–2030 provides the foundation for strengthening early case detection, rapid molecular diagnosis, drug-resistant TB management, contact investigation, preventive treatment, and health system capacity. The Lung Health Initiative Malaysia 2025–2030 further supports an integrated, dual-track strategy addressing both TB infection and active disease through targeted screening, artificial intelligence-assisted chest radiography, shorter treatment regimens, and coordinated healthcare delivery. Achieving TB elimination requires a paradigm shift towards proactive prevention, earlier diagnosis, equitable access, multisectoral collaboration, and measurable program outcomes. Integrating TB services within broader lung health strategies offers Malaysia an opportunity to accelerate progress towards ending TB. Sustained political commitment, adequate financing, community engagement, and robust surveillance will be essential to translate national strategies into impact.
  • Q&A
Ballroom 2, Lower Ground Floor
12:00
13:00
Sponsored by Orient EuroPharma
Mat Zuki Bin Mat Jaeb Chairperson Malaysia
Ballroom 1, Lower Ground Floor